Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Great Basin secures $9.5 million in funding, 3/13

March 2013—Great Basin Corp., a privately held molecular diagnostics company that develops sample-to-result solutions, has raised $9.5 million in series B funding. The funding was led by private investors and will be used to expand manufacturing, fund research and development, and expand global commercialization efforts.

Vitamin D assay, 3/13:72

Tosoh Bioscience’s ST AIA-Pack 25-OH vitamin D assay is for use on most of the company’s AIA system analyzers. Vitamin D measurement is intended as an aid in the determination of vitamin D sufficiency.

HbA1c control assay, 3/13

Streck’s A1c-Cellular HbA1c control with intact red blood cells is now assayed for Roche Diagnostics’ Cobas c311. A1c-Cellular tests the entire HbA1c procedure, including the lysing of the red blood cell. This step ensures that the entire system—instrument and reagents—is working properly and providing accurate patient results. The control is easy to use; it does not require reconstitution, which reduces the potential for human error.

Automated pipetting workstations, 3/13:72

Eppendorf North America’s epMotion M5073 and P5073 workstations automate and simplify complex, labor-intensive pipetting tasks, saving time and improving the reliability and reproducibility of results.

Automated sample prep/LC system, 3/13:72

Thermo Fisher Scientific’s Prelude sample preparation and liquid chromatography (SPLC) system was developed to make analysis of target compounds in complex biological matrices routine for clinical research and forensic toxicology laboratories.

Live data-management program for labs, 3/13:72

Randox Laboratories’ Acusera 24.7 live online is a Web-based interlaboratory data-management program to complement Acusera third-party quality controls and improve quality control processes within the clinical laboratory, while also helping to interpret QC results.

Rapid-response chemiluminescent analyzer, 3/13:72

Inova Diagnostics’ Bio-Flash rapid-response chemiluminescent analyzer is for use by clinical reference and hospital laboratories. Bio-Flash and the company’s Quanta Flash reagents are for autoimmune disease diagnostic testing.

Abbott to adopt cell imaging software for ALK FISH probe test

Abbott and BioView have entered into an agreement in which BioView will develop automated digital-imaging software for use with Abbott’s molecular diagnostic test to detect rearrangements of the ALK gene in patients with advanced non-small cell lung cancer. The software scans lung tissue specimens that have been tested for the ALK gene rearrangement with Abbott’s fluorescence in situ hybridization technology.